A personalised medicine specialist has raised £50 million in Series B funding. Headquartered at the Chesterford Research Park near Cambridge, Microbiotica has developed technology which uses the body’s trillions of resident bacteria – known as the microbiome – to discover and develop therapeutic medicines and biomarkers for a range of disorders and diseases.  The company’s … Continue reading £50m to power personalised medicine specialist